You just read:

Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA®

News provided by

BerGenBio ASA

26 Jun, 2018, 07:31 BST